Augmenix

Augmenix is the private medical company founded in 2008 in Bedford, the State of Massachusetts, and numbering about 140 employees by September, 2018. She developed the SpaceOAR hydrogel intended for reduction of wearisome ghost effects which men can test after radiation therapy concerning a prostate cancer.

History

2018: Boston Scientific purchased Augmenix

On September 6, 2018 the producer of the medical equipment Boston Scientific announced acquisition of Augmenix for $500 million. The buyer promises to pay $100 million more at achievement of certain indicators of sales.

Annually the prostate cancer is revealed at more than 1.1 million men around the world, and about 400,000 of them should undergo local radiation therapy. One of the most widespread complications is radiation injury of the rectum which is exposed to inadvertent radiation because of proximity to a prostate. Introduction of SpaceOAR hydrogel creates an extra space between a rectum and a prostate gland during treatment, thereby reducing a dose of rectal radiation and the related ghost effects.

The patients using SpaceOAR hydrogel noted significant decrease in pain during radiation therapy of a prostate. Besides, at them the number of serious long-term rectal complications significantly decreased – for example, toxic damage of a rectum 2 degrees met at 5.7% of patients in the general group and at 0% in group of hydrogel. One injection of SpaceOAR hydrogel creates a layer between a rectum and a prostate gland for three months – duration of a standard course of radiation therapy. Hydrogel reabsorbirutsya gradually by an organism within six months after an injection.

SpaceOAR hydrogel reduces the frequency of ghost effects at local radiation therapy of a prostate

SpaceOAR hydrogel is registered in Europe and the USA and by September, 2018 more than 30,000 patients are used worldwide. Thanks to Augmenix acquisition by Boston Scientific company, the volume of its sales in 2018 will reach $50 million, and in 2019 — $90 million, predict in the company.^[1]

Notes